Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNA3 | P22001 | 1/20 | 0.38 |
| ▸ | AAK1 | Q2M2I8 | 2/20 | 0.38 |
| ▸ | NSD2 | O96028 | 1/20 | 0.37 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.37 |
| ▸ | RET | P07949 | 3/20 | 0.36 |
| ▸ | ATM | Q13315 | 1/20 | 0.35 |
| ▸ | KCNJ1 | P48048 | 2/20 | 0.34 |
| ▸ | KDM4D | Q6B0I6 | 1/20 | 0.34 |
| ▸ | SUV39H2 | Q9H5I1 | 3/20 | 0.34 |
| ▸ | JAK2 | O60674 | 2/20 | 0.34 |
| ▸ | JAK1 | P23458 | 2/20 | 0.34 |
| ▸ | DRD2 | P14416 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3618787 | 0.90 | KCNA3 (0.36) | KCNA3AAK1ATMKDM4DJAK2 | |
| SCHEMBL3615008 | 0.90 | KCNA3 (0.36) | KCNA3AAK1KCNH2ATMKDM4D | |
| SCHEMBL3609957 | 0.90 | KCNA3 (0.36) | KCNA3AAK1KCNH2ATMKDM4D | |
| SCHEMBL3615723 | 0.83 | KCNH2 (0.40) | KCNH2KCNJ1 | |
| SCHEMBL3611471 | 0.81 | RET (0.35) | AAK1KCNH2RETATMJAK2 | |
| SCHEMBL3606693 | 0.81 | RET (0.35) | AAK1KCNH2RETATMJAK2 | |
| SCHEMBL3618368 | 0.79 | JAK2 (0.37) | JAK2JAK1DRD2 | |
| SCHEMBL3620967 | 0.79 | JAK2 (0.37) | JAK2JAK1DRD2 | |
| SCHEMBL3615396 | 0.77 | JAK2 (0.32) | KCNH2JAK2JAK1 | |
| SCHEMBL4590167 | 0.75 | KCNA3 (0.41) | KCNA3KDM4DSUV39H2DRD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100087424-A1 | TRICYCLIC NITROGEN CONTAINING HETEROCYCLES AS ANTIBACTERIAL AGENTS | GLAXO GROUP LIMITED | 2010-04-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100087424-A1 | TRICYCLIC NITROGEN CONTAINING HETEROCYCLES AS ANTIBACTERIAL AGENTS | NRDC, NDC1, NANS | KCNA3 3759/4885AAK1 4422/4885NSD2 910/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.